Abstract
The use of molecular biomarkers has great potential to drive precision oncology. Although promising, they are not yet widely available in the clinical routine of most medical centers and their high cost can make them unaffordable for most patients. Thus, the development of new fast and low-cost approaches becomes increasingly necessary. In this context, the use of modern techniques of Art…